Contact us Demo our platform

Blog

Metabolomic Analysis Flags Rare and Common Genetic Health Determinants

Genetic Individuality Nature Magazine 2022

A person’s circulating metabolites characterize their unique chemistry and physiology, and factors ranging from genetics to diet to drug-related and disease-related influences contribute.1 Exploring causal correlations between these factors and metabolites thus offers the potential to improve precision medicine.1 A recent study published in Nature Medicine analyzed the relationship between high-confidence causal genes and the metabolites they regulate by leveraging untargeted mass spectrometry methods, noting some key metabolites are impacted by several high-confidence causal genes.1

Leveraging Metabolomics for Genetic Analysis

The results published in the November 2022 cover story of Nature Medicine examined the clinical relevance of various genes across 1,400 phenotypes.1 In particular, the study explored data from 19,994 patients and included plasma levels of over 900 metabolites.1 Classes of metabolites analyzed included nucleotides, peptides, amino acids, lipids, xenobiotics, and carbohydrates as well as others. The researchers leveraged Metabolon’s Global Discovery Panel as part of the untargeted mass spectrometry analysis. Several key findings emerged. Within 330 genomic regions, the study found 2,599 variant-metabolite associations with 646 metabolites.1 Of note, the largest genetic study previously to leverage the Metabolon assay did not report on 225 of the 330 associated genomic regions reported on in this study.2,3

The results from this new study attributed rare variants to 9.4% of associations.1 The study found the highest level of annotated metabolites—94 lipids—associated with the FADS1/FADS2 locus.1 In addition, results detailed pleiotropy both across-class (ABCC1/PLA2G10, ABCG2/PPM1K, AGPAT1, GCKR, and SLC22A1) as well as within-class (MFSD2A and PCSK9).1 Further, the study noted the potential to flag likely adverse drug effects based on specific metabolite-guided discovery.1

Potential Root Causes of Rare Diseases 

Metabolic diseases due to rare genetic variants which result in metabolite accumulation or deficiency are called inborn errors of metabolism (IEMs), and whether untreated or undetected can lead to deleterious phenotypic impacts.4,5 The study noted an eightfold increase of genes among causal genes that result in IEMs.1 In particular, the data showed 88 regions that contained one or more of 97 IEM genes.1 These results have implications for how researchers identify and treat IEMs. 

Implications of Metabolomics for Health Determinants

In sum, this study stands to impact future research by providing a viable pathway for metabolomic analysis to mitigate some of the inherent risks of potential treatments and disease courses seen in past experiments via insight into an individual’s unique chemical individuality.1,6,7

In addition, correlations of known key genes to regulating metabolites have potentially far-reaching implications for scientific research in fields ranging from oncology to rare diseases. Moreover, such data supports efforts toward precision medicine for an array of indications. 

Ready to see what new insights metabolomics can help your research reveal? Contact us today to learn more.

References

  1. Surendran P, Stewart ID., Au Yeung VPW, et al. Rare and common genetic determinants of metabolic individuality and their effects on human health. Nat Med (2022). https://doi.org/10.1038/s41591-022-02046-0
  2. Long T, Hicks M, Yu HC, et al. Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat Genet (2017); 49:568–578. https://doi.org/10.1038/ng.3809
  3. Shin, SY., Fauman, E., Petersen, AK. et al. An atlas of genetic influences on human blood metabolites. Nat Genet (2014); 46:543–550. https://doi.org/10.1038/ng.2982
  4. Campeau PM, Scriver CR, Mitchell JJ. A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. Mol. Genet. Metab (2008). https://doi.org/10.1016/j.ymgme.2008.07.001
  5. Garrod AE. The Incidence of Alkaptonuria: A study in Chemical Individuality. Mol Med (1996); 2:274–282. https://doi.org/10.1007/BF03401625
  6. Zheng JS. et al. Plasma vitamin C and type 2 diabetes: genome-wide association study and Mendelian randomization analysis in European populations. Diabetes Care (2021). https://doi.org/10.2337/dc20-1328
  7. Yarmolinsky J, et al. Circulating selenium and prostate cancer risk: a Mendelian randomization analysis. J. Natl Cancer Inst. (2018). https://doi.org/10.1093/jnci/djy081
Metabolon
Our team is made up of over 45 PhDs, has been published 4,000+ times, and is committed to hard work, excellence, and success through collaboration. With over 15,000 projects, Metabolon has been a trusted partner of researchers for over 25 years.

Topics

Multiomics | Precision Medicine

Share this article

Related Blog Posts

See All Blog Posts

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.